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Response to radiation incidents and radionuclear threats
Medical treatment should be given only
when safe to do so
Editor—Turai et al reviewed the medical
response to radiation incidents and radio-
nuclear threats.1 Puzzlingly, they say that
providing care for a patient in a life
threatening condition always has priority
over decontamination from radioactive
materials or those actions required for the
safety of others involved (medical staff,
emergency rescue teams) or related to the
wider public and environment.1 I disagree.
This statement will encourage inexperi-
enced staff to disregard the safety of
themselves and others in a “heroic” attempt
to treat those ill and injured. The latest edi-
tion of the Major Incident Medical Manage-
ment and Support Course rightly emphasises
self and scene safety over that of survivors.2
Experience has shown again and again that
well meaning but poorly trained or
equipped rescue and medical staff are
highly likely to become further victims.3 As
an example, the article points out that some
of the 28 radiation deaths from the
Chernobyl disaster of 1986 were among
fire fighters.
Medical treatment should be given only
when it is safe to do so: poorly considered
and risky actions will simply lengthen the list
of casualties.
Jonathan R Benger consultant in emergency medicine
Emergency Department, Bristol Royal Infirmary,
Bristol BS2 8HW
Jonathan.Benger@ubht.swest.nhs.uk
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Other threats may be more serious
Editor—I agree with Turai et al that
radiation injury could occur by accident in
countries where disintegrating political enti-
ties such as the former Soviet Union leave
the debris of their nuclear programmes
lying around for an unsuspecting public to
pick up.1 2 However, I am less sure of the real,
as against hysterical, threat in Western
Europe and North America.
Outside closely guarded nuclear power
stations, weapons establishments, and waste
stores the most available stores of radio-
active materials are in hospitals or industry.
Solid sources used in industry and radio-
therapy are well shielded and sealed. If
these seals were broken by a terrorist the
most likely person injured would be him
or her.
The radiation would have to be dis-
persed, presumably by an explosive device.
However, this would not ensure ingestion—
the best way to get a lot of radiation into
someone—and would be easily detected.
Also, once the radiation was dispersed the
activity per person would drop. Such sources
could be used to target an individual, but a
cheap radiation detector as used in airports
or banks would pick up such a source, which
may be quite bulky.
Unsealed sources are found mainly in
hospitals, most of which do not have enough
on site even to kill one person. The most
likely radioisotope is iodine-131, and
32 GBq would need to be administered to
give a 2 Gy dose.3 Such an activity, much
greater than used to treat patients, is unlikely
to be left where it can be easily accessed.
Although radiological bombs grab the
headlines, they are probably much less
dangerous than explosive, chemical, or
microbiological attacks, and it is on these
threats that countermeasures should be
concentrated.
John R Buscombe consultant in nuclear medicine
Royal Free Hospital, London NW3 2QG
j.buscombe@rfc.ucl.ac.uk
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Renunciation of nuclear weapons could
lessen the threat
Editor—We agree with Turai et al in their
review of the medical response to radiation
incidents that the use of nuclear weapons is
currently unlikely,1 but we are concerned
that recent developments could lower the
nuclear threshold worldwide.
Some 20 000 nuclear weapons are active
today, many on high alert. Each is several
times more powerful than the Hiroshima
bomb, which if used on a major city in the
United Kingdom would overwhelm medical
services.2 The United States is planning
“bunker busters” or “mini nukes,” officially
known as “low yield earth penetrating weap-
ons,” claiming that their use would cause less
“collateral damage” from blast or heat than
existing nuclear weapons. However, “vent-
ing” would produce major fallout over
several square kilometres downwind, caus-
ing hundreds of cases of radiation sickness
in urban areas.3
Health workers can support an initiative
towards reducing the nuclear weapon
threat. In May 2005 a review conference of
the Nuclear Non-Proliferation Treaty will
take place at the United Nations. Under
article VI of this treaty, as interpreted by the
International Court of Justice, the nuclear
weapon states are under an obligation to
achieve nuclear disarmament by negotia-
tion at an early date. The UK government
is being urged not to replace Trident (a
decision is needed in the next parliament).
The United Kingdom has renounced
chemical and biological weapons; a similar
step in the nuclear field could lead to
a major reduction in the threat of
nuclear war.4
Douglas Holdstock honorary secretary
Elizabeth Waterston convenor, nuclear hazards group
Medact, Grayston Centre, London N1 6HT
info@medact.org
Competing interests: None declared.
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Authors’ reply
Editor—Benger’s remarks give us an
opportunity to re-emphasise one of the key
messages of our article: saving the lives of
patients with life threatening conditions
should always have a priority, as providing
emergency medical care for a patient
contaminated with radioactive materials
cannot pose a serious direct health risk to
medical staff.
When workers at Chernobyl, who were
in the reactor area at the time of the nuclear
accident, were decontaminated, the medical
staff at the site received less then 10 mGy of
radiation.1 In view of a possible dose as low
such as this, we refer to the handbook of the
Armed Forces Radiobiology Research Insti-
tute, which says that surgical priorities for
acute or life threatening injury must
precede any treatment priority for associ-
ated radiation injury and that radiological
decontamination should never interfere
with medical care.2
We agree with Buscombe that radio-
nuclear threats are of low probability and
the radioactive materials used for making
dirty bombs pose the highest threat to the
terrorists themselves. Accepting that terror-
ist contamination of central water supply
may lead to a serious threat in the affected
population group via ingestion, however, we
wish to underline that inhalation of
radioactive aerosols produced by a radio-
logical dispersion device seems to be the
most probable contamination pathway.
Although hospital sources and radioactive
materials used in nuclear medicine are of
less importance for terrorist use,3 the radio-
therapy sources, when stolen and disman-
tled, may cause severe overexposure to
people having direct contact with them, as
we said in our paper.
We agree with Holdstock and Waterston
that all efforts must be made for non-
proliferation of nuclear weapons. The
Comprehensive Nuclear-Test-Ban Treaty
Organisation (CTBTO, Vienna, www.ctb-
to.org) is the specialised UN organisation in
charge of and effectively performing the
task of preventing proliferation of nuclear
materials.
István Turai medical officer
Department of Protection of the Human
Environment, World Health Organization,
CH-1211 Geneva 27, Switzerland
turaii@who.int
Katalin Veress senior lecturer
Department of Public Health, Semmelweis
University, Budapest, Hungary
Bengül Günalp associate professor
Department of Nuclear Medicine, Gülhane Medical
Academy, Ankara, Turkey
Gennadi Souchkevitch deputy director
Institute of Pathology and Pathophysiology,
Moscow, Russia
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Penetrating ocular trauma from
an exploding microwaved egg
Editor—Microwave heating results in posi-
tive pressure, especially in food confined by
a membrane. Eggs with intact shells, intact
egg yolks in open shells, and even pierced
yolks can explode when microwaved.
Exploding microwaved eggs or eggshells
have caused facial, eyelid, and corneal burns
of varying severity.1 One published case of
intraocular trauma from an exploding
microwaved egg presented as an anterior
chamber epithelial inclusion cyst two years
later.2 We report a case of serious ocular
trauma from an exploding microwaved egg.
A 9 year old girl reheated a previously
boiled egg (with an intact shell) using a
domestic microwave oven at full power for
about 40 seconds. The heated egg was
removed from the microwave oven and
placed in a bowl. Around 30 seconds later, as
she was carrying it to the dining area, the
egg exploded with part of it hitting her right
eye and face.
She sustained a full thickness corneal
perforation and rupture of the anterior lens
capsule, reducing her vision to being able to
see only hand movements. After primary cor-
neal repair and then cataract aspiration with
intraocular lens insertion three months later
(figure), visual acuity recovered to 6/6
unaided and posterior segment examination
was normal.
In their instruction manuals manufactur-
ers of microwave ovens warn against heating
eggs with an intact shell and recommend
multiple piercing before cooking or heating
eggs, even those already boiled. In view of the
potential seriousness of injury from explod-
ing microwaved eggs, such warnings should
be made more obvious, possibly being
displayed on the microwave oven itself.
Saurabh Goyal specialist registrar in ophthalmology
Queen Mary’s Hospital, Sidcup, Kent DA14 6LT
sgoyal@doctors.org.uk
Yee Fong Choong specialist registrar in
ophthalmology
Wagih A Aclimandos consultant ophthalmologist
Roger L Coakes consultant ophthalmologist
King’s College Hospital, London SE5 9RS
Competing interests: None declared.
1 Wolf Y, Adler N, Hauben DJ. Exploding microwaved eggs—
revisited. Burns 2001;27:853-5.
2 DeMatteo MP, Vrabec MP. Intraocular trauma from a
microwave oven. Am J Ophthalmol 1992;114:99-100.
Management of anorexia
nervosa revisited
Emphasis needs to continue to shift to
outpatient care
Editor—Russell argues that funding should
be more readily available for the private
inpatient treatment of anorexia nervosa.1
She says that “some patients” need inpatient
care, but she does not say which patients.
This is the crux of the problem.
Inpatient care will continue to be used in
some of the most difficult cases, but it should
be viewed with caution. I am disappointed
that Russell (and her reviewers) did not
mention the important paper by Gowers et
al, which showed that patients who had
received inpatient care did rather worse than
those who were treated only as outpatients.2
Our own clinical experience reflects this.
We run a child and adolescent eating
disorders service for five primary care trusts
in north London. The area we cover had
previously had between nine and 12 admis-
sions a year to the private sector. With the
setting up of our outpatient focused team,
the number of admissions has been reduced
to one a year, or a total of six admissions
over the past six years. This has produced a
saving to the local NHS of at least £400 000
a year, while achieving very satisfactory
clinical outcomes, and with no formal
complaints and no untoward events.
We still work closely with two inpatient
units, one NHS and one private, whose
contribution we value greatly and to which we
will continue to refer patients. But even very
good and dedicated inpatient care has not
greatly modified the clinical course of some
of the six adolescents who became inpatients.
Inpatient care costs perhaps 10 times as
much as outpatient care. Clear clinical
benefits of inpatient treatment over outpa-
tient treatment have not yet been identified.
Furthermore, inpatient care may have some
adverse consequences. Therefore, while I
will continue to fight for resources to send a
minority of my patients to the very best
inpatient units, the emphasis now should
undoubtedly be on good outpatient care.
Mark Berelowitz consultant child and adolescent
psychiatrist
Royal Free Hampstead NHS Trust, London
NW3 2QG
mark.berelowitz@royalfree.nhs.uk
Competing interests: MB and his colleagues run
an outpatient based service for children and ado-
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Drug treatment suggestions are
questionable
Editor—I am concerned that Russell in her
editorial suggested that reboxetine and
venlafaxine be used “early” in anorexia.1
This seems to be on the back of some
tenuous genetic work and not on the basis
of clinical trials.
Intraoperative photograph of traumatic cataract and
repaired corneal perforation after injury by exploding
microwaved egg
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I express this concern because these are
“new antidepressants” with many years of
profit to run for the pharmaceutical compa-
nies. We must be very circumspect about
these new drugs until adequate clinical
research supports their use over more tradi-
tional drugs. How many of the new psycho-
active wonder drugs have in fact delivered a
mental health utopia? What happened to
the Prozac generation? Are they still
smiling?
Des Spence general practitioner
Maryhill Health Centre, Glasgow G20 9DR
destwo@yahoo.co.uk
Competing interests: DS supports nofreelunch
UK.
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Author’s reply
Editor—I agree with Berelowitz that outpa-
tient treatment is no less deserving of
adequate funding than inpatient—
particularly as most patients spend consid-
erably more time as outpatients. Certainly
Gowers is a cogent detractor of inpatient
care in adolescent anorexia nervosa, and
despite his generalisations about quality of
inpatient settings, in principle, I have no
argument with his assertion.1
Ideally, outpatient family therapy and
medical support should be preferable. How-
ever, in our experience this is not always the
case for various reasons. A specialised medi-
cal psychiatric inpatient programme with
suitable milieu would be expected to
manage eating disorders better than could a
general paediatric or adolescent medical
setting, and preliminary evaluation of our
own programme supports this contention.2 I
plead for provision of an appropriate level
of specialist care, both inpatient and
outpatient, as many patients require both.
I emphasise that I was simply suggesting
on the basis of molecular genetic data (as
sound as any available) that noradrenergic
agents should be considered in treating
depressed patients with anorexia nervosa
(restrictive subtype).3 4 Our studies were not
supported by a drug company. We found
good responses with the addition of
reboxetine to a selective serotonin reuptake
inhibitor and to venlafaxine when there
has been little or no response to selective
serotonin reuptake inhibitors alone.
Janice Russell clinical associate professor and medical
director
Eating Disorders Program, Northside Clinic,
Greenwich, NSW 2065, Australia
jrussel1@mail.usyd.edu.au
Competing interests: JR is also the director of a
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Aspirin induced asthma
Clinical relevance of finding was not
explained
Editor—The prevalence of aspirin induced
asthma on oral provocation testing in the sys-
tematic review by Jenkins et al was deter-
mined at 21%, which is noticeably higher
than verbal history (2-3%) and recent reviews
(10%).1–3 The clinical relevance of this finding
is not explained. What was the degree of
bronchospasm? In how many patients was it
easily reversed by a dose of inhaler?
As anaesthetists we agree fully with the
authors’ recommendations about the
dangers of giving non-steroidal anti-
inflammatory drugs (NSAIDs) to patients
with known sensitivity to aspirin. We also
recognise that people with nasal polyps and
asthma are at higher risk of aspirin sensitiv-
ity. It is the large proportion of patients who
are left for whom we have an issue.
The recommendation to organise a test
before administration would be difficult in
the current NHS. The authors’ guidelines
recommend that anyone younger than 40
should have a trial of drug treatment under
supervision, or should be prescribed an
NSAID only if absolutely necessary. This
could be accommodated postoperatively in
hospital, but not when NSAIDs are given to
patients to take home—for example, after
day case surgery. How long do Jenkins et al
recommend the patients be observed for?
We do not want this paper to cause
anaesthetists, emergency doctors, and sur-
geons to deny these useful drugs to patients
with asthma. A balanced approach taking
into account risks and benefits is always
necessary. This review, even with the admis-
sion of bias in the paper, shows that 80% of
asthmatic patients can take these drugs.
Indu Sivanandan clinical fellow anaesthetics
sindu@doctors.org.uk
Stephen M Robinson consultant anaesthetist
Southmead Hospital, Bristol BS10 5NB
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Effect size needs to be clarified
Editor—Jenkins et al describe the pooled
data for the risk of aspirin induced asthma,
and by implication all asthma induced by
non-steroidal anti-inflammatory drugs
(NSAIDs).1 NSAIDs are an important group
of medicines in the treatment of acute pain
after injury. Not all patients are, however,
able to tolerate them because of respiratory
or gastrointestinal side effects.
It is accepted that more patients are
being diagnosed as asthmatic, so is it true
that NSAIDs can be prescribed to fewer
patients? The trials that were pooled for the
meta-analysis had differing selection crite-
ria. It would be fair to comment that the
population used for the study is one where
the asthma is more severe—asthma clinics
and admissions for acute exacerbations. It
would be fair to say that most patients with
asthma are managed in the community
without any problems. To say that anyone
under 40 should have a witnessed trial of
treatment under supervision or should be
prescribed an NSAID only if absolutely nec-
essary will reduce the amount that a useful
class of drugs are used. Would this be a valid
exclusion from the four hour target the gov-
ernment has set for accident and emergency
departments or would doctors therefore
have to admit everyone to an observation
unit that may not be there merely to
prescribe a safe drug?
The appropriate question is not whether
it causes bronchospasm but whether it is
clinically relevant. What is the incidence of
admission to hospital or need for nebulisers
in the asthmatic population after NSAID
administration? A four fifths rate of no
bronchospasm in the group studied indi-
cates that NSAIDs are safe and doctors
should continue to use them.
Robert D Southward consultant in accident and
emergency medicine
University Hospital of Hartlepool, Hartlepool
TS24 9AH
robertdougal.southward@nth.nhs.uk
Competing interests: None declared.
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Authors’ reply
Editor—We agree with Sivanandan and
Robinson that the recommendation to
organise a test before administration of
aspirin would be difficult in routine clinical
practice. Our advice regarding formal
provocation testing and medical supervision
for the first dose is simply to maximise
safety. When this is not possible, clear advice
should be given about the risks, and the
availability of bronchodilators should be
ensured. The onset of aspirin induced bron-
choconstriction occurs within one hour, and
in our experience the worst reactions occur
within two hours.
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We concur that the converse of our
findings is that four out of five patients with
asthma are safe with respect to risk of
sensitivity to aspirin or non-steroidal anti-
inflammatory drugs (NSAIDs). This is reas-
suring, and it is important not to over-react by
saying that all asthmatic patients should avoid
aspirin or NSAIDs. In view of the high preva-
lence of asthma in the community and the
likelihood of occasional purchase of over the
counter simple analgesics, we believe simple,
standardised warnings on packs of aspirin
and NSAIDs are appropriate.
We agree with Southward that there is
heterogeneity of study populations in our
meta-analysis. We tried to overcome this by
grouping subjects according to the clinical
history. Most of the patients were selected
from tertiary hospital outpatient clinics and
almost certainly represent a group of
patients with more severe asthma than
patients who never present to hospital. More
studies are required to determine the preva-
lence and severity of aspirin sensitive asthma
in the total asthma population.
Christine Jenkins head, asthma group
Woolcock Institute of Medical Research,
Camperdown, NSW 2050, Australia
crj@mail.med.usyd.edu.au
John Costello clinical director of medicine
King’s College Hospital, London SE5 9RS
Linda Hodge dietitian
Clontarf, NSW 2093, Australia
Competing interests: CJ has received payment
from GlaxoSmithKline Consumer Healthcare
Australia, the manufacturer of Panadol (paraceta-
mol), for speaking at a conference. JC serves as a
consultant on the Global Analgesics Advisory
Board, which is funded by GlaxoSmithKline
Consumer Healthcare.
E is for equivocal in EBM
Editor—Straus asks what’s the E for EBM
(evidence based medicine).1 E is for equivocal
because that’s the best assessment of most
published, controlled, double blind research
studies (no matter the medical journal).
The evidence for EBM is inherently
unreliable for four reasons.
Firstly, a large volume of research
funded by drug companies is not allowed by
them to be submitted for publication.2 3
Secondly, totally unsuitable patients are
sometimes recruited into sensitive drug trials,
and only a few such patients are needed to
invalidate the conclusions of studies. There is
no way when doing peer reviewing or reading
the paper after publication that this can be
detected. I have noticed this only from
reading the paper, carefully going through a
patient’s notes, and talking to the patient at
length. I have seen this in diabetes research,
but it could be common in areas of medical
research because no one usually has the time,
the position, and the information to check for
such practices.
Thirdly, some papers are ghost written.3 4
We will never know how many research
papers this practice applies to but it is likely
to be substantial. In addition, some chosen
professors or doctors who put their names
on research papers have never seen the raw
data, let alone know how accurately they
have been written up.
Fourthly, bias has an effect. Whether bias
is intentionally or unintentionally introduced
by researchers, doctors, statisticians, or ghost-
writers, the effect is difficult to measure.
Declared and undeclared interest is one
element,5 but bias occurs in so many other
ways that to publish a double blind research
paper without it seems almost impossible.
Matthew R Kiln principal in general practice
Rosendale Surgery, London SE21 8EZ
lkiln@AOL.com
Competing interests: MRK is cochairman of a
patient support charity.
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Revalidation: swallow hard
Editor—Sometime in 2005 (but who knows
exactly when), all the 100 000 or so doctors
in the United Kingdom will be subject to
revalidation.1–3
Despite the gravity of this change in the
licensing of medical practitioners, there has
been and still is little debate on this matter.
Read through, for example, van Zwanen-
berg’s references and you will have read just
about all that has been published about it.2
Revalidation will affect the lives of every
doctor registered with the GMC, yet few
seem concerned about its process, implica-
tions, or repercussions. Compare the flood
of responses to Wald and Law’s paper on the
Polypill with what is barely a trickle to the
two papers on revalidation.1–4 Are we all dis-
tracted by contract worries, or are we
burying our heads in the sand? Our new
contracts will determine how much money
goes into our pocket, but failing revalidation
might render us unemployed.
Bruce et al provide one of the few
published trials on the process of revalida-
tion.1 But their trial is based on the views of
only 53 doctors (who were volunteers). Soon
all the doctors in Scotland will have the
choice of following their model of revalida-
tion or engaging in a bit of do-it-yourself
revalidation. They are lucky: in the rest of the
United Kingdom, there is even less to go on.
Only unsupported statements from the
GMC such as: “We believe that full
participation in annual appraisal, with com-
pleted supporting documentation, during
the revalidation cycle, is a powerful indicator
of a doctor’s current fitness to practise.”3
If I told you I had a drug called “Revali-
dation,” but it had no clear indication, little
research had been done on its efficacy, and
nothing had been done on its effectiveness,
cost effectiveness, or safety profile, would
you swallow it?
You won’t have a choice come 2005.
Geoff Wong general practitioner principal
The Surgery, 5 Daleham Gardens, London
NW3 5BY
g.wong@pcps.ucl.ac.uk
Competing interests: None declared.
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Continuing medical education:
does “no evidence” trump all?
Editor—Patel, a cardiology fellow at Duke
Clinical Research Institute, told the BMJ that
no studies have been done to show whether
continuing education is working.1 This
sentence reports his views, but it does not
quote him directly, attach any conditional
comments, or set in context. In the
circumstances we should excuse Patel and
the BMJ for a misleading statement.
According to a Cochrane review, “Inter-
active workshops can result in moderately
large changes in professional practice.”2
Incidentally, the same review shows no effect
from “didactic” teaching sessions—that is,
lectures to large audiences.
Thus continuing professional develop-
ment is capable of changing professional
practice. And workshop style programmes
are commonplace in the United Kingdom
(and much enjoyed by participants). It would
probably be correct to say that no studies
have shown a global effect of all the continu-
ing professional development happening
on all the practice and healthcare outcomes
that are supposed to ensue. And that most
studies of its effect are confined to localities
or individual programmes.
Would methodologically rigorous large
scale studies be possible? Or worth the effort?
Does anyone else get a little irritated by
the lazy rhetorical device of crying out: “no
evidence,” as if that trumps all?
Michael F Loudon freelance general practitioner
Newark, Nottinghamshire NG22 0AG
michael@hillsidehouse.co.uk
Competing interests: MFL is involved in a
freelance project evaluating a continuing profes-
sional development programme for Mansfield
and District Primary Care Trust.
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